Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Found 3423 publications
Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator: Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator: Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Tolvaptan - Comprehensive patent search US$ 6,200.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator:Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Simeprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Simeprevir indications: Treatment of chronic hepatitis C infection in combination with Peginterferon alfa and Ribavirin, or with Sofosbuvir and optionally Ribavirin innovator: Janssen Pharm (Olysio, Galexos) Country Coverage: ...

Sep, 2014
Simeprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and results This report covers: International Nonproprietary Name: Simeprevir indications: Treatment of chronic hepatitis C infection in combination with Peginterferon alfa and Ribavirin, or with Sofosbuvir and optionally Ribavirin innovator: Janssen Pharm (Olysio, Galexos) Country Coverage: Albania ...

Sep, 2014
Mirabegron - Comprehensive patent search US$ 6,201.00

... , save searches and results This report covers: International Nonproprietary Name: Mirabegron indications: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency innovator:Astellas (Myrbetriq, Betmiga) Country coverage: The In-depth search contains ...

Sep, 2014
Ledipasvir - Comprehensive patent search US$ 7,500.00

... searches and results This report covers: International Nonproprietary Name: Ledipasvir indications: Treatment of chronic HCV infection in combination with Sofosbuvir innovator:Gilead Country coverage: The In-depth search contains patents from territories that are individually verified and monitored ...

Sep, 2014
Elvitegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator: Gilead (Stribild); Gilead ( ...

Sep, 2014
Elvitegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator: Gilead (Stribild); Gilead ( ...

Sep, 2014
Elvitegravir - Comprehensive patent search US$ 7,500.00

... This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator:Gilead (Stribild); Gilead (Vitekta); ...

Sep, 2014
Aflibercept - Comprehensive patent search US$ 9,300.00

... of neovascular wet age-related macular degeneration; Treatment of macular edema following central retinal vein occlusion; Treatment of metastatic colorectal cancer that is resistant to or has progressed following an Oxaliplatin-containing regimen in combination with 5-Fluorouracil, Leucovorin and Irinotecan ...

Sep, 2014
Abatacept - Comprehensive patent search US$ 9,300.00

... indications: Treatment of adult rheumatoid arthritis, optionally in combination with DMARDs optionally other than TNF antagonists; Treatment of juvenile idiopathic arthritis, optionally in combination with Methotrexate; Treatment of juvenile rheumatoid arthritis innovator:Bristol Myers Squibb (Orencia) ...

Sep, 2014
Global Erectile Dysfunction Drugs Market 2014-2018 US$ 2,500.00

... and effective therapies. TechNavio's analysts forecast the Global Erectile Dysfunction Drugs market to decline at a CAGR of 4.47 percent over the period 2013- ... . The report includes a discussion of the key vendors operating in this market. Key Regions Americas APAC EMEA Key Vendors Apricus Biosciences ...

Sep, 2014 77 pages
Pediatric Drug Development - Regulatory Challenges and Commercial Opportunities US$ 2,995.00

... Pediatric vaccines Key Reasons to Purchase Reviews the current regulatory landscape and helps sponsors to understand the potential impact of FDA SIA regulations ... plans; Identifies the key challenges associated with pediatric drug development and the ways to overcome these hurdles; Assesses what issues ...

Jul, 2014 64 pages
Adaptive Licensing - A Holistic Approach to Drug Development and Regulation US$ 2,995.00

... and registries. Data from ongoing RCTs, and the more robust data from post-license surveillance studies are used to determine full ... and political changes will be necessary to realize the full potential of AL. Scope Adaptive Licensing: Overview Introduction A Declining Industry – How AL can tackle issues ...

Jul, 2014 79 pages
Alzheimer's Disease Drug Pipeline, Diagnostics and Biomarkers: New Developments, Growth Areas and Opportunities US$ 3,016.00

... of the drug development pipeline relating to Alzheimer's disease, which has been analysed alongside commercially available or developmental minimally-invasive AD diagnostics and ... studies involving AD patients (and those with (presumed) early-stage disease) and studies published over the last five year, 40,000 ...

Sep, 2014 185 pages
The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth US$ 900.00

... growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing ... held a market share of ~% and recorded sales of USD ~ million. The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.4% with ...

Jul, 2014 144 pages
Drug Discovery Technologies - A Global Market Overview US$ 3,060.00

... field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Worldwide market for drug discovery technologies explored in this study includes Bioanalytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, ...

Aug, 2014 248 pages
US CNS Disorders Drug Pipeline Insight 2014 US$ 2,400.00

... purchasing Hard Copy License depending on the location. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry ... with launch of novel drugs will drive the growth of CNS disease market in future. “US CNS Disorders Drug Pipeline Insight 2014” Report ...

Aug, 2014 1700 pages
Global Multiple Sclerosis Drugs Market 2014-2018 US$ 3,000.00

... the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market ... Acorda Active Biotech GlaxoSmithKline Glenmark Mitsubishi Tanabe Opexa Pfizer Sanofi Market Driver Unmet Medical Needs For a full, detailed list, view our ...

Aug, 2014 102 pages
US Orphan Drug Clinical Pipeline Insight 2014 US$ 2,000.00

... disorders, which are extremely life-threatening. As per the official definition, rare diseases are classified as those that affect fewer than 200, ... & FDA Regulatory Framework US Orphan Drug Pipeline by Phase, Indication & Company Marketed Orphan Drug Clinical Insight US Orphan Drug Clinical Pipeline: 570 ...

Aug, 2014 2000 pages
Global HIV Infection Drug Market & Pipeline Insight US$ 2,400.00

... cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years. The access ... are less promising. “Global HIV Infection Drug Market & Pipeline Insight” Report Highlight: Global HIV Infection Drug Market Overview & Incidence Scenario FDA ...

Aug, 2014 1350 pages
Global Intranasal Drug Delivery Market 2014-2018 US$ 2,500.00

... and enhanced bioavailability. TechNavio's analysts forecast the Global Intranasal Drug Delivery market to grow at a CAGR of 2.92 percent over the period 2013- ... . The report includes a discussion of the key vendors operating in this market. Key Regions Americas APAC EMEA Key Vendors Becton, Dickinson ...

Aug, 2014 70 pages
Global Peptic Ulcer Drugs Market 2014-2018 US$ 2,500.00

... the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 2014–2018. To calculate the ... Pozen Rottapharm Madaus Taiho Pharmaceutical Zeria Pharmaceutical Zuventus Healthcare Market Driver Increased Incidence of H. pylori Infections. For a full, detailed list, ...

Aug, 2014 83 pages
2014 Deep Research Report on Global and China Diabetes Drugs Industry US$ 2,200.00

2014 Deep Research Report on Global and China Diabetes Drugs Industry was professional and depth research report on Global and China ... application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis ...

Aug, 2014 166 pages
Substance (Drug) Abuse-Pipeline Insights, 2014 US$ 1,250.00

SUMMARY DelveInsight’s,“ Substance (Drug) Abuse-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key ... projects and understanding the factors that drove them from pipeline Gaining a Full Picture of the Competitive Landscape for Evidence based ...

Aug, 2014
Investment Opportunity in Emerging Flexible Packaging Sector in India- How & Why to Invest, Market Potential, Target Consumers, Business Feasibility, Project Financials (Laminated... US$ 500.00

... titled ‘Investment Opportunity in Emerging Flexible Packaging Sector in India- How & Why to Invest, Market Potential, Target Consumers, Business Feasibility, Project Financials ... burgeoning middle class and low per capita consumption levels will encourage the industry growth. The report moves ahead to discuss ...

Jul, 2014 41 pages
Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 US$ 9,995.00

... from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made ... Intec’s CD/LD-GR. - Analysis of the current and future market competition in the global Parkinson’s disease market. Insightful review of the key industry and governmental ...

Mar, 2014 327 pages
T - Bact-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “T - Bact - Drug Insights, 2014” provides T - Bact marketed details and API Manufacturers details across the globe ... strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Somavert-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Somavert - Drug Insights, 2014” provides Somavert marketed details and API Manufacturers details across the globe ... strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Telzir -Drug Insights,2014 US$ 1,000.00

... SUMMARY DelveInsight’s pharmaceuticals report, “Telzir - Drug Insights, 2014” provides Telzir marketed details and API Manufacturers details across the globe ... and industry-specific sources Coverage of the Marketed data of the Telzir on the basis of MOA, target, dosage, route of administration, molecule type ...

Jul, 2014
Latuda-Drug Insights,2014 US$ 1,000.00

... SUMMARY DelveInsight’s pharmaceuticals report, “Latuda - Drug Insights, 2014” provides Latuda marketed details and API Manufacturers details across the globe ... and industry-specific sources Coverage of the Marketed data of the Latuda on the basis of MOA, target, dosage, route of administration, molecule type ...

Jul, 2014
Selzentry-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Selzentry - Drug Insights, 2014” provides Selzentry marketed details and API Manufacturers details across the globe along ... , Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Fusilev-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Fusilev - Drug Insights, 2014” provides Fusilev marketed details and API Manufacturers details across the globe ... , strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Vertiserc-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Vertiserc - Drug Insights, 2014” provides Vertiserc marketed details and API Manufacturers details across the globe along ... , Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Revoleyd -Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Revoleyd - Drug Insights, 2014” provides Revoleyd marketed details and API Manufacturers details across the globe ... strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Xenazine-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Xenazine - Drug Insights, 2014” provides Xenazine marketed details and API Manufacturers details across the globe ... strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Zenhale-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Zenhale - Drug Insights, 2014” provides Zenhale marketed details and API Manufacturers details across the globe ... , strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Toviaz-Drug Insights,2014 US$ 1,000.00

... SUMMARY DelveInsight’s pharmaceuticals report, “Toviaz - Drug Insights, 2014” provides Toviaz marketed details and API Manufacturers details across the globe ... and industry-specific sources Coverage of the Marketed data of the Toviaz on the basis of MOA, target, dosage, route of administration, molecule type ...

Jul, 2014
Edirol-Drug Insights,2014 US$ 1,000.00

... SUMMARY DelveInsight’s pharmaceuticals report, “Edirol - Drug Insights, 2014” provides Edirol marketed details and API Manufacturers details across the globe ... and industry-specific sources Coverage of the Marketed data of the Edirol on the basis of MOA, target, dosage, route of administration, molecule type ...

Jul, 2014
Zortress-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Zortress - Drug Insights, 2014” provides Zortress marketed details and API Manufacturers details across the globe ... strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Talion-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Talion OD - Drug Insights, 2014” provides Talion OD marketed details and API Manufacturers details across the globe along ... , Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Flutide Nasal Pumpspray-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Flutide Nasal Pumpspray - Drug Insights, 2014” provides Flutide Nasal Pumpspray marketed details and API Manufacturers ... , Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API ...

Jul, 2014
Integrilin-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Integrilin - Drug Insights, 2014” provides Integrilin marketed details and API Manufacturers details across the globe ... , Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API ...

Jul, 2014
Teribone-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Teribone - Drug Insights, 2014” provides Teribone marketed details and API Manufacturers details across the globe ... strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Zerinol Throat Mint-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Zerinol Throat Mint - Drug Insights, 2014” provides Zerinol Throat Mint marketed details and API Manufacturers ... , strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Zaldiar-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Zaldiar - Drug Insights, 2014” provides Zaldiar marketed details and API Manufacturers details across the globe ... , strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and ...

Jul, 2014
Flolan-Drug Insights,2014 US$ 1,000.00

... SUMMARY DelveInsight’s pharmaceuticals report, “Flolan - Drug Insights, 2014” provides Flolan marketed details and API Manufacturers details across the globe ... and industry-specific sources Coverage of the Marketed data of the Flolan on the basis of MOA, target, dosage, route of administration, molecule type ...

Jul, 2014
Selera-Drug Insights,2014 US$ 1,000.00

... SUMMARY DelveInsight’s pharmaceuticals report, “Selera - Drug Insights, 2014” provides Selera marketed details and API Manufacturers details across the globe ... and industry-specific sources Coverage of the Marketed data of the Selera on the basis of MOA, target, dosage, route of administration, molecule type ...

Jul, 2014
Omez Mups-Drug Insights,2014 US$ 1,000.00

SUMMARY DelveInsight’s pharmaceuticals report, “Omez Mups - Drug Insights, 2014” provides Omez Mups marketed details and API Manufacturers details across the ... strength, Chemical type and ATC Classification Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API ...

Jul, 2014
1 2 3 4 5 >
Skip to top